The U.S. Agency for International Development (USAID) submits this report pursuant to Section 7019(e) of Division G of Public Law 116-94, the Department of State, Foreign Operations, and Related Programs Appropriations Act, 2020, which incorporates by reference the requirements of House Report 116-78 and Senate Report 116-126.

Senate Report 116-126: Not later than 60 days after enactment of the act, the USAID Administrator shall submit the annual report to the appropriate congressional committees on USAID’s health-related research and development strategy, which shall include: (1) specific health product development goals, including timelines for product development; (2) details about ongoing and planned investments in drugs, vaccines, diagnostics, and devices, including collaboration with other Federal agencies as well as private sector partners; (3) a detailed description of the mechanisms for collaboration and coordination in support of global health product development between Federal agencies; (4) an assessment of any critical gaps in product development for global health; and (5) recommendations for filling such gaps to ensure that U.S. investments in global health research are efficient, coordinated, and effective.

USAID funds research and development (R&D) in global health that focuses on advancing new technologies and innovative approaches to increase efficiencies, address critical unmet needs, and improve the impact of health programs. Priority updates from Fiscal Year (FY) 2019 in these two areas appear below.